After 2026-01-30, Winkles Isabelle's BRZE filings point to a sequence worth tracking
Winkles Isabelle's BRZE insider record stands at $17.5M cumulative sales (latest filing 2026-01-30); focus on sequence, transaction-code mix, and ownership trend over time.
Winkles Isabelle continues to shape the insider narrative for BRZE. Cumulative sales are $17.5M, but the higher-value insight is in how filings cluster around 2026-01-30 and after.
Recent Form 4 Prints
| Date | Code | Shares | Price | Est. Value |
|---|---|---|---|---|
| 2026-01-30 | J | 40,000 | $35.01 | $1.4M |
| 2026-01-30 | J | 40,000 | $35.01 | $1.4M |
| 2026-01-30 | J | 120,000 | $35.01 | $4.2M |
| 2026-01-30 | J | 120,000 | $35.01 | $4.2M |
| 2026-01-30 | J | 36,281 | $4.88 | $177K |
| 2026-01-30 | J | 36,281 | $4.88 | $177K |
| 2025-11-18 | S | 12,422 | $26.64 | $331K |
| 2025-09-04 | C | 8,532 | N/A | N/A |
Context for Braze, Inc.
In headline-sensitive environments, insider prints are easy to overread. A disciplined approach is to watch persistence outside expected liquidity windows.
Search-Based Context
Current search results for industry context
Bottom Line
Informative signal, not yet decisive; wait for follow-through data.
Related Research
Explore all researchPrincipal’s Q4 2025 filing looked slightly weaker on headline AUM, but the internal rotation was more revealing: Brookfield became a top-ten position, Netflix surged, and the fund cut back in parts of real estate. The next filing will show whether that shift keeps going.
Apr 17, 2026
Nuveen’s Q4 2025 filing stayed large-cap and AI-heavy at the top, but the more revealing addition was a sizable fixed-income sleeve through NXUS and NHYB. The next filing will show whether those credit and bond ETFs remain central or fade back out.
Apr 17, 2026
Fisher’s Q4 2025 filing was still packed with mega-cap tech, but the bigger tell was a giant Treasury and investment-grade corporate bond sleeve built through IEF and VCIT. The next filing will show whether that duration bet was tactical or structural.
Apr 17, 2026
Dodge & Cox’s Q4 2025 filing barely moved on headline AUM, but the underlying changes were more interesting: fresh positions in Brookfield, TransUnion and PDD inside a still-diversified value book. The next filing will show whether those adds were conviction moves or just incremental reshuffling.
Apr 17, 2026
AQR’s Q4 2025 filing kept expanding, with AUM rising to $190.63B, 69 new names, and a dramatic Bristol Myers build inside an already broad book. The next filing will show whether the quant giant keeps pressing this expansion or starts normalizing the roster again.
Apr 17, 2026